A profibrotic role for thymic stromal lymphopoietin in Systemic sclerosis

Annals of the Rheumatic Diseases

Volumn 72, Issue 12, 2013, Pages 2018-2029

  Usategui, Alicia ^a   Criado, Gabriel ^a   Izquierdo, Elena ^a   Del Rey, Manuel J ^a   Carreira, Patricia E ^a   Ortiz, Pablo ^a   Leonard, Warren J ^b   Pablos, José L ^a  

^a Universidad Complutense   (Spain)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 13; INTERLEUKIN 17; MESSENGER RNA; THYMIC STROMAL LYMPHOPOIETIN; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR AGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; FIBROBLAST CULTURE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG FIBROSIS; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMIC SCLEROSIS; TH2 CELL; TSLP GENE;

AUTOIMMUNITY; CYTOKINES; FIBROBLASTS; SYSTEMIC SCLEROSIS;

ANIMALS; BLEOMYCIN; CELLS, CULTURED; CYTOKINES; FEMALE; FIBROBLASTS; FIBROSIS; GENE EXPRESSION REGULATION; HUMANS; MICE; MICE, INBRED C3H; PULMONARY FIBROSIS; RNA, MESSENGER; SCLERODERMA, SYSTEMIC; SKIN; TOLL-LIKE RECEPTORS;

EID: 84887425714     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202279     Document Type: Article

References (44)

1. Cho JH, Gregersen PK. Genomics and the multifactorial nature of human autoimmune disease. N Engl J Med 2011;365:1612-23.
2. Craddock N, Hurles ME, Cardin N, et al. Genome-wide association study of CNVs in 16, 000 cases of eight common diseases and 3, 000 shared controls. Nature 2010;464:713-20.
3. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007;117:557-67.
4. Whitfield ML, Finlay DR, Murray JI, et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 2003;100:12319-4.
5. Wynn TA. Integrating mechanisms of pulmonary fibrosis. J Exp Med 2011;208:1339-50.
6. Meneghin A, Hogaboam CM. Infectious disease, the innate immune response, and fibrosis. J Clin Invest 2007;117:530-8.
7. Aliprantis AO, Wang J, Fathman JW, et al. Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13. Proc Natl Acad Sci USA 2007;104:2827-30.
8. Radstake TR, van Bon L, Broen J, et al. The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes. PLoS One 2009;4:e5903.
9. Parel Y, Aurrand-Lions M, Scheja A, et al. Presence of CD4+CD8+ double-positive T cells with very high interleukin-4 production potential in lesional skin of patients with systemic sclerosis. Arthritis Rheum 2007;56:3459-67.
10. Boin F, De Fanis U, Bartlett SJ, et al. T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease. Arthritis Rheum 2008;58:1165-74.
11. Truchetet ME, Brembilla NC, Montanari E, et al. Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease. Arthritis Res Ther 2011;13:R166.
12. van Bon L, Popa C, Huijbens R, et al. Distinct evolution of TLR-mediated dendritic cell cytokine secretion in patients with limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2010;69:1539-47.
13. Ito T, Wang YH, Duramad O, et al. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J Exp Med 2005;202:1213-23.
14. Soumelis V, Reche PA, Kanzler H, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 2002;3:673-80.
15. Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T cells by gamma (c) family cytokines. Nat Rev Immunol 2009;9:480-90.
16. Ying S, O'Connor B, Ratoff J, et al. Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity. J Immunol 2005;174:8183-90.
17. Al-Shami A, Spolski R, Kelly J, et al. A role for TSLP in the development of inflammation in an asthma model. J Exp Med 2005;202:829-39.
18. Lee HC, Ziegler SF. Inducible expression of the proallergic cytokine thymic stromal lymphopoietin in airway epithelial cells is controlled by NFkappaB. Proc Natl Acad Sci USA. 2007;104:914-19.
19. Kato A, Favoreto S Jr, Avila PC, et al. TLR3-and Th2 cytokine-dependent production of thymic stromal lymphopoietin in human airway epithelial cells. J Immunol 2007;179:1080-7.
20. Bogiatzi SI, Fernandez I, Bichet JC, et al. Cutting edge: proinflammatory and Th2 cytokines synergize to induce thymic stromal lymphopoietin production by human skin keratinocytes. J Immunol 2007;178:3373-7.
21. Oh MH, Oh SY, Yu J, et al. IL-13 induces skin fibrosis in atopic dermatitis by thymic stromal lymphopoietin. J Immunol 2011;186:7232-42.
22. Ramalingam TR, Pesce JT, Mentink-Kane MM, et al. Regulation of helminth-induced Th2 responses by thymic stromal lymphopoietin. J Immunol 2009;182:6452-9.
23. Santiago B, Gutierrez-Canas I, Dotor J, et al. Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis. J Invest Dermatol 2005;125:450-5.
24. Al-Shami A, Spolski R, Kelly J, et al. A role for thymic stromal lymphopoietin in CD4 (+) T cell development. J Exp Med 2004;200:159-68.
25. Razonable RR, Henault M, Paya CV. Stimulation of toll-like receptor 2 with bleomycin results in cellular activation and secretion of pro-inflammatory cytokines and chemokines. Toxicol Appl Pharmacol 2006;210:181-9.
26. Yang HZ, Cui B, Liu HZ, et al. Targeting TLR2 attenuates pulmonary inflammation and fibrosis by reversion of suppressive immune microenvironment. J Immunol 2009;182:692-702.
27. Yamamoto T, Nishioka K. Animal model of sclerotic skin. IV: induction of dermal sclerosis by bleomycin is T cell independent. J Invest Dermatol 2001;117:999-1001.
28. Matsushita M, Yamamoto T, Nishioka K. Upregulation of interleukin-13 and its receptor in a murine model of bleomycin-induced scleroderma. Int Arch Allergy Immunol 2004;135:348-56.
29. Lakos G, Melichian D, Wu M, et al. Increased bleomycin-induced skin fibrosis in mice lacking the Th1-specific transcription factor T-bet. Pathobiology 2006;73:224-37.
30. Fichtner-Feigl S, Strober W, Kawakami K, et al. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 2006;12:99-106.
31. Hartgring SA, Willis CR, Dean CE, et al. Critical proinflammatory role of thymic stromal lymphopoietin and its receptor in experimental autoimmune arthritis. Arthritis Rheum 2011;63:1878-87.
32. Tanaka J, Watanabe N, Kido M, et al. Human TSLP and TLR3 ligands promote differentiation of Th17 cells with a central memory phenotype under Th2-polarizing conditions. Clin Exp Allergy 2009;39:89-100.
33. Aden N, Nuttall A, Shiwen X, et al. Epithelial cells promote fibroblast activation via IL-1alpha in systemic sclerosis. J Invest Dermatol 2010;130:2191-200.
34. Mori H, Kawada K, Zhang P, et al. Bleomycin-induced pulmonary fibrosis in genetically mast cell-deficient WBB6F1-W/Wv mice and mechanism of the suppressive effect of tranilast, an antiallergic drug inhibiting mediator release from mast cells, on fibrosis. Int Arch Allergy Appl Immunol 1991;95:195-201.
35. Seibold JR, Giorno RC, Claman HN. Dermal mast cell degranulation in systemic sclerosis. Arthritis Rheum 1990;33:1702-9.
36. Yamamoto T, Takahashi Y, Takagawa S, et al. Animal model of sclerotic skin. II. Bleomycin induced scleroderma in genetically mast cell deficient WBB6F1-W/W (V) mice. J Rheumatol 1999;26:2628-34.
37. Schulman ES. The role of mast cells in inflammatory responses in the lung. Crit Rev Immunol 1993;13:35-70.
38. Miyata M, Hatsushika K, Ando T, et al. Mast cell regulation of epithelial TSLP expression plays an important role in the development of allergic rhinitis. Eur J Immunol 2008;38:1487-92.
39. Hepworth MR, Danilowicz-Luebert E, Rausch S, et al. Mast cells orchestrate type 2 immunity to helminths through regulation of tissue-derived cytokines. Proc Natl Acad Sci USA 2012;109:6644-9.
40. Farina GA, York MR, Di Marzio M, et al. Poly (I:C) drives type I IFN-and TGFbeta-mediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosis. J Invest Dermatol 2010;130:2583-93.
41. Agarwal SK, Wu M, Livingston CK, et al. Toll-like receptor 3 upregulation by type I interferon in healthy and scleroderma dermal fibroblasts. Arthritis Res Ther 2011;13:R3.
42. Ozawa T, Koyama K, Ando T, et al. Thymic stromal lymphopoietin secretion of synovial fibroblasts is positively and negatively regulated by Toll-like receptors/nuclear factor-kappaB pathway and interferon-gamma/dexamethasone. Mod Rheumatol 2007;17:459-63.
43. Yamada T, Saito H, Kimura Y, et al. CpG-DNA suppresses poly (I:C)-induced TSLP production in human laryngeal arytenoid fibroblasts. Cytokine 2012;57:245-50.
44. Leadbetter EA, Rifkin IR, Hohlbaum AM, et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002;416:603-7.